Abstract：
Huntington\'s disease (HD) is a hereditary condition considered by the progressive degeneration of nerve cells in the brain, resultant in motor dysfunction and cognitive impairment. Despite current treatment modalities including pharmaceuticals and various therapies, a definitive cure remains elusive. Therefore, this study investigates the therapeutic potential effect of Apelin-13 in HD management. Thirty male Wistar rats were allocated into three groups: a control group, a group with HD, and a group with both HD and administered Apelin-13. Apelin-13 was administered continuously over a 28-day period at a dosage of around 30 mg/kg to mitigate inflammation in rats subjected to 3-NP injection within an experimental HD model. Behavioral tests, such as rotarod, electromyography (EMG), elevated plus maze, and open field assessments, demonstrated that Apelin-13 improved motor function and coordination in rats injected with 3-NP. Apelin-13 treatment significantly increased neuronal density and decreased glial cell counts compared to the control group. Immunohistochemistry analysis revealed reduced gliosis and expression of inflammatory factors in the treatment group. Moreover, Apelin-13 administration led to elevated levels of glutathione and reduced reactive oxygen species (ROS) level in the treated group. Apelin-13 demonstrates neuroprotective effects, leading to improved movement and reduced inflammatory and fibrotic factors in the HD model.
摘要：
亨廷顿病（HD）是一种遗传性疾病，被认为是大脑中神经细胞的进行性变性，导致运动功能障碍和认知障碍。尽管目前的治疗方式包括药物和各种疗法，最终的治疗仍然难以捉摸。因此,本研究调查了Apelin-13在HD管理中的潜在治疗效果.将30只雄性Wistar大鼠分为三组：对照组，一组有HD,以及同时患有HD和施用Apelin-13的组。在28天的时间内以约30mg/kg的剂量连续施用Apelin-13,以减轻在实验性HD模型中进行3-NP注射的大鼠的炎症。行为测试,如旋转杆，肌电图（EMG），高架加上迷宫，和开放的实地评估，表明Apelin-13改善了注射3-NP的大鼠的运动功能和协调性。与对照组相比,Apelin-13处理显著增加神经元密度和减少神经胶质细胞计数。免疫组织化学分析显示治疗组神经胶质增生和炎症因子表达减少。此外，Apelin-13给药导致治疗组中谷胱甘肽水平升高和活性氧(ROS)水平降低。Apelin-13显示神经保护作用，导致HD模型中运动改善和炎症和纤维化因子减少。
